Pharmacia & Upjohn Company

Elan Pharmaceuticals, Inc.

Other

Robert L Heinrikson

Mark E Gurney

Riqiang Yan

Michael Jerome Bienkowski

Luis A Parodi

Alfredo Giuseppe Tomasselli

Thomas L Emmons

Ana Mildner

Donna Paddock

Samuel B Ho

Kenneth A Koeplinger

Laurie Shekels

Ronald J Shebuski

Michael J Bienkowaki

Michael B Fairbanks

Isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same are described. The MUC17, Muc3 or MUC3 derived polypeptides, polynucleotides, and pharmaceutical compositions can be used to treat gastrointestinal tract diseases and disorders including, inflammatory bowel disease and its associated colitides, for example, Crohn's Disease.

Mucin derived polypeptides

The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a &#x3b2;-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.

Substrates and assays for &#x3b2;-secretase

The present invention provides the enzyme and enzymatic procedures for cleaving the &#x3b2; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.

Alzheimer's disease secretase

The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1&#xb0; C. to 15&#xb0; C., and incubating the diluted sample at a temperature of about 4&#xb0; C. to 15&#xb0; C. until the recombinant BACE polypeptide folds into an active enzyme.

Method for refolding enzymes

The present invention provides the enzyme and enzymatic procedures for cleaving the &#x3b2; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

Alzheimer's disease secretase, APP substrates therefor, and uses therefor

Substrates and assays for &#x3b2;-secretase activity

The present invention provides the enzyme and enzymatic procedures for cleaving the &#x3b2; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

Alzheimer's disease secretase, APP substrates therefor, and uses thereof

The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.

The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

Growing community of inventors

Plainwell, MI, United States of America

Robert L Heinrikson